Dr. Jeffrey J. Kirshner
Claim this profileHematology Oncology Associates of Central New York-East Syracuse
Studies Lung Cancer
Studies Breast Cancer
26 reported clinical trials
50 drugs studied
About Jeffrey J. Kirshner
Education:
- Obtained MD from the State University of New York at Buffalo, School of Medicine and Biomedical Sciences (1986).
- Completed Residency in Internal Medicine at the University of Rochester Medical Center (1989).
- Finished Fellowship in Hematology/Oncology at the University of Rochester Medical Center (1991).
Experience:
- Affiliated with Hematology Oncology Associates of Central New York-East Syracuse as a hematologist and oncologist.
Area of expertise
1Lung Cancer
Stage III
Stage IV
Stage II
2Breast Cancer
HER2 positive
ER positive
ER negative
Affiliated Hospitals
Clinical Trials Jeffrey J. Kirshner is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
More about Jeffrey J. Kirshner
Clinical Trial Related6 years of experience running clinical trials · Led 26 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Jeffrey J. Kirshner has experience with
- Carboplatin
- Atezolizumab
- Paclitaxel
- Pembrolizumab
- Leucovorin Calcium
- Fluorouracil
Breakdown of trials Jeffrey J. Kirshner has run
Lung Cancer
Breast Cancer
Breast cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jeffrey J. Kirshner specialize in?
Jeffrey J. Kirshner focuses on Lung Cancer and Breast Cancer. In particular, much of their work with Lung Cancer has involved Stage III patients, or patients who are Stage IV.
Is Jeffrey J. Kirshner currently recruiting for clinical trials?
Yes, Jeffrey J. Kirshner is currently recruiting for 6 clinical trials in East Syracuse New York. If you're interested in participating, you should apply.
Are there any treatments that Jeffrey J. Kirshner has studied deeply?
Yes, Jeffrey J. Kirshner has studied treatments such as Carboplatin, Atezolizumab, Paclitaxel.
What is the best way to schedule an appointment with Jeffrey J. Kirshner?
Apply for one of the trials that Jeffrey J. Kirshner is conducting.
What is the office address of Jeffrey J. Kirshner?
The office of Jeffrey J. Kirshner is located at: Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse, New York 13057 United States. This is the address for their practice at the Hematology Oncology Associates of Central New York-East Syracuse.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.